{"symbol":"BMY","fiscalQuarter":"Q4-2024","reportDate":"2025-02-06","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q4-2024","postBrief":{"headline":"Bristol-Myers Squibb Beats on EPS, Stock Down 3.84%","keyNumbers":[{"metric":"EPS","actual":"$1.67","expected":"N/A","surprise":"+14.15%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Unknown","keyQuotes":[],"summary":"No transcript is on record, and the analysis is based on numerical results only."},"guidanceChanges":{"summary":"No guidance data is available.","changes":[]},"whatItMeans":"Bristol-Myers Squibb reported better-than-expected earnings per share, exceeding estimates by 14.15%. However, the stock fell by 3.84% following the announcement, indicating that investors may have been disappointed by the lack of revenue information and guidance. The market reaction suggests uncertainty about the company's future performance.","metaDescription":"Bristol-Myers Squibb (BMY) Q4 2024 earnings: EPS beat by 14.15%. Stock down 3.84%. Full breakdown."}}